ArticleScientific reports2022
Development and validation of multivariate models integrating preoperative clinicopathological and radiographic findings to predict HER2 status in gastric cancer.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Interpretable intratumoral and peritumoral radiomics using SHAP for predicting microsatellite status in gastric adenocarcinoma: a dual-center study.Frontiers in oncology · 2026Article
- Predicting human epidermal growth factor receptor 2 status of patients with gastric cancer by computed tomography and clinical features.Gastroenterology report · 2024Article
- Prediction of HER2 status via random forest in 3257 Chinese patients with gastric cancer.Clinical and experimental medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of trastuzumab and chemotherapy is recommended as first-line therapy for patients with human epidermal growth factor receptor 2 (HER2) positive advanced gastric cancers (GCs). Successful trastuzumab-induced targeted therapy should be based on the assessment of HER2 overexpression. This study aimed to evaluate the feasibility of multivariate models based on hematological parameters, endoscopic biopsy, and computed tomography (CT) findings for assessing HER2 overexpression in GC. This retrospective study included 183 patients with GC, and they were divided into primary (n = 137) and validation (n = 46) cohorts at a ratio of 3:1. Hematological parameters, endoscopic biopsy, CT morphological characteristics, and CT value-related and texture parameters of all patients were collected and analyzed. The mean corpuscular hemoglobin concentration value, morphological type, 3 CT value-related parameters, and 22 texture parameters in three contrast-enhanced phases differed significantly between the two groups (all p < 0.05). Multivariate models based on the regression analysis and support vector machine algorithm achieved areas under the curve of 0.818 and 0.879 in the primary cohort, respectively. The combination of hematological parameters, CT morphological characteristics, CT value-related and texture parameters could predict HER2 overexpression in GCs with satisfactory diagnostic efficiency. The decision curve analysis confirmed the clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.